61:@0.895357:0.033217:0.916054:0.033217:0.916054:0.013052:0.895357:0.013052:0.010348:0.010348
HANDBOOK OF GENERAL MEDICINE VOL 1:@0.649278:0.972666:0.923020:0.972666:0.923020:0.958637:0.649278:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
TREATMENT AppROACHEs:@0.983817:0.243404:0.983817:0.056390:0.958557:0.056390:0.958557:0.243404:0.008796:-0.015759:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.114251:0.006043:0.014598:-0.134892:0.158618:-0.158618:0.000000:0.000000:0.000000:0.000000:0.242660:0.009202
TREATMENT AppROACHEs:@0.397039:0.033156:0.624383:0.033156:0.624383:0.013866:0.397039:0.013866:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
table 5. trials with GlP-1 therapeutics:@0.078571:0.593622:0.350412:0.593622:0.350412:0.577123:0.078571:0.577123:0.006350:0.009979:0.009979:0.003629:0.009676:0.004233:0.008467:0.004233:0.004233:0.006350:0.004838:0.003629:0.009979:0.003629:0.006652:0.004233:0.012095:0.003629:0.004536:0.009071:0.004233:0.012700:0.006652:0.008467:0.006350:0.008467:0.004233:0.004536:0.009071:0.009676:0.004838:0.009979:0.009979:0.009676:0.009071:0.004536:0.003629:0.009676:0.006652
elixA:@0.215754:0.609562:0.251502:0.609562:0.251502:0.594897:0.215754:0.594897:0.006988:0.005913:0.003763:0.009139:0.009945
leADer:@0.394118:0.609562:0.441155:0.609562:0.441155:0.594897:0.394118:0.594897:0.005913:0.006988:0.009945:0.009407:0.006988:0.007795
sustAin-6:@0.572483:0.609562:0.637528:0.609562:0.637528:0.594897:0.572483:0.594897:0.006988:0.008601:0.006988:0.005644:0.009945:0.003763:0.009945:0.005644:0.007526
exsCel:@0.750847:0.609562:0.797346:0.609562:0.797346:0.594897:0.750847:0.594897:0.006988:0.009139:0.006988:0.010483:0.006988:0.005913
medication:@0.083271:0.624956:0.157455:0.624956:0.157455:0.610291:0.083271:0.610291:0.012095:0.008601:0.008870:0.003225:0.008601:0.008870:0.004032:0.003225:0.008601:0.008063
Lixisenatide:@0.215767:0.624956:0.290314:0.624956:0.290314:0.610927:0.215767:0.610927:0.006209:0.002688:0.006451:0.002688:0.005214:0.008735:0.008198:0.009179:0.004556:0.002688:0.009206:0.008735
Liraglutide:@0.394132:0.624956:0.461341:0.624956:0.461341:0.610927:0.394132:0.610927:0.006209:0.002688:0.004045:0.009179:0.009045:0.002688:0.008171:0.004556:0.002688:0.009206:0.008735
semaglutide:@0.572496:0.624956:0.654797:0.624956:0.654797:0.610927:0.572496:0.610927:0.006693:0.008735:0.012606:0.009179:0.009045:0.002688:0.008171:0.004556:0.002688:0.009206:0.008735
Exenatide:@0.750860:0.624956:0.815812:0.624956:0.815812:0.610927:0.750860:0.610927:0.007203:0.006451:0.008735:0.008198:0.009179:0.004556:0.002688:0.009206:0.008735
# Patients:@0.083284:0.640350:0.145373:0.640350:0.145373:0.625685:0.083284:0.625685:0.008063:0.003763:0.007526:0.008870:0.004032:0.003225:0.008601:0.008063:0.004032:0.005913
6 068:@0.215781:0.640350:0.249285:0.640350:0.249285:0.626321:0.215781:0.626321:0.007445:0.003723:0.007445:0.007445:0.007445
9 340:@0.394145:0.640350:0.427649:0.640350:0.427649:0.626321:0.394145:0.626321:0.007445:0.003723:0.007445:0.007445:0.007445
2 735:@0.572509:0.640350:0.606013:0.640350:0.606013:0.626321:0.572509:0.626321:0.007445:0.003723:0.007445:0.007445:0.007445
14 000:@0.750874:0.640350:0.791823:0.640350:0.791823:0.626321:0.750874:0.626321:0.007445:0.007445:0.003723:0.007445:0.007445:0.007445
History:@0.083298:0.655744:0.126303:0.655744:0.126303:0.641078:0.083298:0.641078:0.009139:0.003225:0.005913:0.004032:0.008601:0.004301:0.007795
T2D, acute coronary :@0.215794:0.655744:0.352161:0.655744:0.352161:0.641715:0.215794:0.641715:0.005725:0.007445:0.009999:0.003723:0.003723:0.009179:0.008695:0.008171:0.004556:0.008735:0.003723:0.008695:0.008803:0.004045:0.008803:0.008198:0.009179:0.004045:0.007203:0.003723
event within 180 days :@0.215794:0.668572:0.358988:0.668572:0.358988:0.654543:0.215794:0.654543:0.008735:0.007445:0.008735:0.008198:0.004556:0.003723:0.011168:0.002688:0.004556:0.008198:0.002688:0.008198:0.003723:0.007445:0.007445:0.007445:0.003723:0.009206:0.009179:0.007203:0.005214:0.003723
prior to randomisation:@0.215794:0.681400:0.358706:0.681400:0.358706:0.667371:0.215794:0.667371:0.009165:0.004045:0.002688:0.008803:0.004045:0.003723:0.004556:0.008803:0.003723:0.004045:0.009179:0.008198:0.009206:0.008803:0.012606:0.002688:0.005214:0.009179:0.004556:0.002688:0.008803:0.008198
T2D, high-risk CVD:@0.394159:0.655744:0.510138:0.655744:0.510138:0.641715:0.394159:0.641715:0.005725:0.007445:0.009999:0.003723:0.003723:0.008198:0.002688:0.009045:0.008198:0.004462:0.004045:0.002688:0.005214:0.006746:0.003723:0.010926:0.009434:0.009999
T2D, high-risk CVD:@0.572523:0.655744:0.688503:0.655744:0.688503:0.641715:0.572523:0.641715:0.005725:0.007445:0.009999:0.003723:0.003723:0.008198:0.002688:0.009045:0.008198:0.004462:0.004045:0.002688:0.005214:0.006746:0.003723:0.010926:0.009434:0.009999
T2D, with prior CV events :@0.750887:0.655744:0.914993:0.655744:0.914993:0.641715:0.750887:0.641715:0.005725:0.007445:0.009999:0.003723:0.003723:0.011168:0.002688:0.004556:0.008198:0.003723:0.009165:0.004045:0.002688:0.008803:0.004045:0.003723:0.010926:0.009434:0.003723:0.008735:0.007445:0.008735:0.008198:0.004556:0.005214:0.003723
and/or with or w/o known :@0.750887:0.668572:0.922895:0.668572:0.922895:0.654543:0.750887:0.654543:0.009179:0.008198:0.009206:0.005873:0.008803:0.004045:0.003642:0.011168:0.002688:0.004556:0.008198:0.003642:0.008803:0.004045:0.003642:0.011168:0.005873:0.008803:0.003642:0.006746:0.008198:0.008803:0.011168:0.008198:0.003723
CV risks:@0.750887:0.681400:0.798878:0.681400:0.798878:0.667371:0.750887:0.667371:0.010926:0.009434:0.003723:0.004045:0.002688:0.005214:0.006746:0.005214
study design:@0.083311:0.696794:0.166365:0.696794:0.166365:0.682129:0.083311:0.682129:0.006988:0.004032:0.008063:0.008870:0.007795:0.003763:0.008870:0.008601:0.005913:0.003225:0.008870:0.008063
Multi-centre, randomised,  Multi-centre, double-:@0.215808:0.696794:0.530727:0.696794:0.530727:0.682765:0.215808:0.682765:0.012351:0.008171:0.002688:0.004556:0.002688:0.004462:0.008695:0.008735:0.008198:0.004556:0.004045:0.008735:0.003723:0.003723:0.004045:0.009179:0.008198:0.009206:0.008803:0.012606:0.002688:0.005214:0.008735:0.009206:0.003723:0.003723:0.007714:0.012351:0.008171:0.002688:0.004556:0.002688:0.004462:0.008695:0.008735:0.008198:0.004556:0.004045:0.008735:0.003723:0.003723:0.009206:0.008803:0.008171:0.009165:0.002688:0.008735:0.004462
double-blind, placebo-:@0.215808:0.709622:0.367321:0.709622:0.367321:0.695593:0.215808:0.695593:0.009206:0.008803:0.008171:0.009165:0.002688:0.008735:0.004462:0.009165:0.002688:0.002688:0.008198:0.009206:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.004462
controlled; non-inferiority, trolled; non-inferiority,:@0.215808:0.722451:0.533590:0.722451:0.533590:0.708422:0.215808:0.708422:0.008695:0.008803:0.008198:0.004556:0.004045:0.008803:0.002688:0.002688:0.008735:0.009206:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462:0.002688:0.008198:0.004220:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203:0.003723:0.013251:0.004556:0.004045:0.008803:0.002688:0.002688:0.008735:0.009206:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462:0.002688:0.008198:0.004220:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203:0.003723
superiority:@0.215808:0.735279:0.281122:0.735279:0.281122:0.721250:0.215808:0.721250:0.005214:0.008171:0.009165:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203
blind, placebo-con-:@0.394172:0.709622:0.524612:0.709622:0.524612:0.695593:0.394172:0.695593:0.009165:0.002688:0.002688:0.008198:0.009206:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.004462:0.008695:0.008803:0.008198:0.004462
superiority:@0.394172:0.735279:0.459486:0.735279:0.459486:0.721250:0.394172:0.721250:0.005214:0.008171:0.009165:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203
Multi-centre, double-:@0.572536:0.696794:0.709091:0.696794:0.709091:0.682765:0.572536:0.682765:0.012351:0.008171:0.002688:0.004556:0.002688:0.004462:0.008695:0.008735:0.008198:0.004556:0.004045:0.008735:0.003723:0.003723:0.009206:0.008803:0.008171:0.009165:0.002688:0.008735:0.004462
blind, placebo-con-:@0.572536:0.709622:0.702977:0.709622:0.702977:0.695593:0.572536:0.695593:0.009165:0.002688:0.002688:0.008198:0.009206:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.004462:0.008695:0.008803:0.008198:0.004462
trolled; non-inferiority,:@0.572536:0.722451:0.711954:0.722451:0.711954:0.708422:0.572536:0.708422:0.004556:0.004045:0.008803:0.002688:0.002688:0.008735:0.009206:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462:0.002688:0.008198:0.004220:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203:0.003723
superiority:@0.572536:0.735279:0.637851:0.735279:0.637851:0.721250:0.572536:0.721250:0.005214:0.008171:0.009165:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203
phase 3/4 multi-centre, :@0.750901:0.696794:0.903972:0.696794:0.903972:0.682765:0.750901:0.682765:0.007956:0.008198:0.009179:0.005214:0.008735:0.003723:0.007445:0.005873:0.007445:0.003723:0.012606:0.008171:0.002688:0.004556:0.002688:0.004462:0.008695:0.008735:0.008198:0.004556:0.004045:0.008735:0.003723:0.003723
randomised, double-:@0.750901:0.709622:0.887456:0.709622:0.887456:0.695593:0.750901:0.695593:0.004045:0.009179:0.008198:0.009206:0.008803:0.012606:0.002688:0.005214:0.008735:0.009206:0.003723:0.003723:0.009206:0.008803:0.008171:0.009165:0.002688:0.008735:0.004462
blind, placebo-con-:@0.750901:0.722451:0.881341:0.722451:0.881341:0.708422:0.750901:0.708422:0.009165:0.002688:0.002688:0.008198:0.009206:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.004462:0.008695:0.008803:0.008198:0.004462
trolled, parallel-group:@0.750901:0.735279:0.891125:0.735279:0.891125:0.721250:0.750901:0.721250:0.004556:0.004045:0.008803:0.002688:0.002688:0.008735:0.009206:0.003723:0.003723:0.009165:0.009179:0.004045:0.009179:0.002688:0.002688:0.008735:0.002688:0.004462:0.009045:0.004045:0.008803:0.008171:0.009165
Primary outcome:@0.083325:0.750673:0.194869:0.750673:0.194869:0.736008:0.083325:0.736008:0.007526:0.004301:0.003225:0.012633:0.008870:0.004301:0.007795:0.003763:0.008601:0.008063:0.004032:0.008601:0.008601:0.012633:0.008601
4-point mACe::@0.215821:0.750673:0.308820:0.750673:0.308820:0.736008:0.215821:0.736008:0.007526:0.005644:0.008870:0.008601:0.003225:0.008063:0.004032:0.003763:0.012095:0.009945:0.010483:0.006988:0.003763
 CV death, :@0.308807:0.750673:0.383931:0.750673:0.383931:0.736644:0.308807:0.736644:0.003723:0.010926:0.009434:0.003723:0.009206:0.008735:0.009179:0.004556:0.008198:0.003723:0.003723
non-fatal MI, non-fatal :@0.215821:0.763501:0.365063:0.763501:0.365063:0.749472:0.215821:0.749472:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723:0.012351:0.003037:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723
stroke, hospitalisation for :@0.215821:0.776330:0.377696:0.776330:0.377696:0.762301:0.215821:0.762301:0.005214:0.004556:0.004045:0.008803:0.006746:0.008735:0.003723:0.003723:0.008198:0.008803:0.005214:0.009165:0.002688:0.004556:0.009179:0.002688:0.002688:0.005214:0.009179:0.004556:0.002688:0.008803:0.008198:0.003723:0.004220:0.008803:0.004045:0.003723
unstable angina (coro-:@0.215821:0.789158:0.365412:0.789158:0.365412:0.775129:0.215821:0.775129:0.008171:0.008198:0.005214:0.004556:0.009179:0.009165:0.002688:0.008735:0.003723:0.009179:0.008198:0.009045:0.002688:0.008198:0.009179:0.003723:0.004959:0.008695:0.008803:0.004045:0.008789:0.004462
nary revascularisation):@0.215821:0.801986:0.361851:0.801986:0.361851:0.787957:0.215821:0.787957:0.008198:0.009179:0.004045:0.007203:0.003723:0.004045:0.008735:0.007445:0.009179:0.005214:0.008695:0.008171:0.002688:0.009179:0.004045:0.002688:0.005214:0.009179:0.004556:0.002688:0.008803:0.008198:0.004959
3-point mACe:@0.394185:0.750673:0.483421:0.750673:0.483421:0.736008:0.394185:0.736008:0.007526:0.005644:0.008870:0.008601:0.003225:0.008063:0.004032:0.003763:0.012095:0.009945:0.010483:0.006988
: CV death, :@0.483408:0.750673:0.562255:0.750673:0.562255:0.736644:0.483408:0.736644:0.003723:0.003723:0.010926:0.009434:0.003723:0.009206:0.008735:0.009179:0.004556:0.008198:0.003723:0.003723
non-fatal MI, non-fatal :@0.394185:0.763501:0.543427:0.763501:0.543427:0.749472:0.394185:0.749472:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723:0.012351:0.003037:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723
stroke:@0.394185:0.776330:0.432285:0.776330:0.432285:0.762301:0.394185:0.762301:0.005214:0.004556:0.004045:0.008803:0.006746:0.008735
3-point mACe: :@0.572550:0.750673:0.669312:0.750673:0.669312:0.736008:0.572550:0.736008:0.007526:0.005644:0.008870:0.008601:0.003225:0.008063:0.004032:0.003763:0.012095:0.009945:0.010483:0.006988:0.003763:0.003763
CV death, :@0.669298:0.750673:0.740700:0.750673:0.740700:0.736644:0.669298:0.736644:0.010926:0.009434:0.003723:0.009206:0.008735:0.009179:0.004556:0.008198:0.003723:0.003723
non-fatal MI, non-fatal :@0.572550:0.763501:0.721791:0.763501:0.721791:0.749472:0.572550:0.749472:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723:0.012351:0.003037:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723
stroke:@0.572550:0.776330:0.610650:0.776330:0.610650:0.762301:0.572550:0.762301:0.005214:0.004556:0.004045:0.008803:0.006746:0.008735
3-point mACe: :@0.750914:0.750673:0.847676:0.750673:0.847676:0.736008:0.750914:0.736008:0.007526:0.005644:0.008870:0.008601:0.003225:0.008063:0.004032:0.003763:0.012095:0.009945:0.010483:0.006988:0.003763:0.003763
CV death, :@0.847662:0.750673:0.919065:0.750673:0.919065:0.736644:0.847662:0.736644:0.010926:0.009434:0.003723:0.009206:0.008735:0.009179:0.004556:0.008198:0.003723:0.003723
non-fatal MI, non-fatal :@0.750914:0.763501:0.900156:0.763501:0.900156:0.749472:0.750914:0.749472:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723:0.012351:0.003037:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723
stroke:@0.750914:0.776330:0.789014:0.776330:0.789014:0.762301:0.750914:0.762301:0.005214:0.004556:0.004045:0.008803:0.006746:0.008735
results:@0.083338:0.817380:0.126881:0.817380:0.126881:0.802715:0.083338:0.802715:0.007795:0.008601:0.005913:0.008063:0.003225:0.004032:0.005913
Lixisenatide group: 13.4%:@0.215835:0.817380:0.377252:0.817380:0.377252:0.803351:0.215835:0.803351:0.006209:0.002688:0.006451:0.002688:0.005214:0.008735:0.008198:0.009179:0.004556:0.002688:0.009206:0.008735:0.003723:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723:0.003723:0.007445:0.007445:0.003723:0.007445:0.010415
placebo group: 13.2%:@0.215835:0.830208:0.357927:0.830208:0.357927:0.816179:0.215835:0.816179:0.007956:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723:0.003723:0.007445:0.007445:0.003723:0.007445:0.010415
HR 1.02; 95% Cl 0.89-1.17:@0.215835:0.843037:0.373341:0.843037:0.373341:0.829008:0.215835:0.829008:0.009179:0.008158:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.003723:0.007445:0.007445:0.010415:0.003723:0.010926:0.002688:0.003723:0.007445:0.003723:0.007445:0.007445:0.004462:0.007445:0.003723:0.007445:0.007445
P <0.001 for non-inferiority P <0.001 for non-inferiority:@0.215835:0.855865:0.559567:0.855865:0.559567:0.841836:0.215835:0.841836:0.007956:0.003723:0.008144:0.007445:0.003723:0.007445:0.007445:0.007445:0.003723:0.004220:0.008803:0.004045:0.003723:0.008198:0.008803:0.008198:0.004462:0.002688:0.008198:0.004220:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203:0.012996:0.007956:0.003723:0.008144:0.007445:0.003723:0.007445:0.007445:0.007445:0.003723:0.004220:0.008803:0.004045:0.003723:0.008198:0.008803:0.008198:0.004462:0.002688:0.008198:0.004220:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203
p = 0.81 for superiority:@0.215835:0.868693:0.355266:0.868693:0.355266:0.854664:0.215835:0.854664:0.007956:0.003723:0.008144:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.004220:0.008803:0.004045:0.003723:0.005214:0.008171:0.009165:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203
Liraglutide group: 13.0%:@0.394199:0.817380:0.548279:0.817380:0.548279:0.803351:0.394199:0.803351:0.006209:0.002688:0.004045:0.009179:0.009045:0.002688:0.008171:0.004556:0.002688:0.009206:0.008735:0.003723:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723:0.003723:0.007445:0.007445:0.003723:0.007445:0.010415
placebo group: 14.9%:@0.394199:0.830208:0.536291:0.830208:0.536291:0.816179:0.394199:0.816179:0.007956:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723:0.003723:0.007445:0.007445:0.003723:0.007445:0.010415
HR 0.87; 95% Cl 0.78-0.97:@0.394199:0.843037:0.551706:0.843037:0.551706:0.829008:0.394199:0.829008:0.009179:0.008158:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.003723:0.007445:0.007445:0.010415:0.003723:0.010926:0.002688:0.003723:0.007445:0.003723:0.007445:0.007445:0.004462:0.007445:0.003723:0.007445:0.007445
p = 0.01 for superiority:@0.394199:0.868693:0.533630:0.868693:0.533630:0.854664:0.394199:0.854664:0.007956:0.003723:0.008144:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.004220:0.008803:0.004045:0.003723:0.005214:0.008171:0.009165:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203
semaglutide group: 6.6%:@0.572563:0.817380:0.734290:0.817380:0.734290:0.803351:0.572563:0.803351:0.006693:0.008735:0.012606:0.009179:0.009045:0.002688:0.008171:0.004556:0.002688:0.009206:0.008735:0.003723:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723:0.003723:0.007445:0.003723:0.007445:0.010415
placebo group: 8.9%:@0.572563:0.830208:0.707210:0.830208:0.707210:0.816179:0.572563:0.816179:0.007956:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723:0.003723:0.007445:0.003723:0.007445:0.010415
HR 0.74: 95% Cl, 0.58 to :@0.572563:0.843037:0.724076:0.843037:0.724076:0.829008:0.572563:0.829008:0.009179:0.008158:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.003723:0.007445:0.007445:0.010415:0.003723:0.010926:0.002688:0.003723:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.004556:0.008803:0.003723
0.95:@0.572563:0.855865:0.598622:0.855865:0.598622:0.841836:0.572563:0.841836:0.007445:0.003723:0.007445:0.007445
P <0.001 for non-inferiority:@0.572563:0.868693:0.737932:0.868693:0.737932:0.854664:0.572563:0.854664:0.007956:0.003723:0.008144:0.007445:0.003723:0.007445:0.007445:0.007445:0.003723:0.004220:0.008803:0.004045:0.003723:0.008198:0.008803:0.008198:0.004462:0.002688:0.008198:0.004220:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203
Ongoing:@0.750927:0.817380:0.808581:0.817380:0.808581:0.803351:0.750927:0.803351:0.011679:0.008198:0.009045:0.008803:0.002688:0.008198:0.009045
Additional  :@0.083351:0.884087:0.157791:0.884087:0.157791:0.869422:0.083351:0.869422:0.009945:0.008870:0.008870:0.003225:0.004032:0.003225:0.008601:0.008063:0.008870:0.003225:0.003750:0.003763
benefits/risks:@0.083351:0.896915:0.167749:0.896915:0.167749:0.882250:0.083351:0.882250:0.008870:0.008601:0.008063:0.008601:0.003494:0.003494:0.004032:0.005913:0.006182:0.004301:0.003225:0.005913:0.007795:0.005913
Reduction in all-cause :@0.394212:0.884087:0.542486:0.884087:0.542486:0.870058:0.394212:0.870058:0.008158:0.008735:0.009206:0.008171:0.008695:0.004556:0.002688:0.008803:0.008198:0.003723:0.002688:0.008198:0.003723:0.009179:0.002688:0.002688:0.004462:0.008695:0.009179:0.008171:0.005214:0.008735:0.003723
mortality in Rx group :@0.394212:0.896915:0.530149:0.896915:0.530149:0.882886:0.394212:0.882886:0.012606:0.008803:0.004045:0.004556:0.009179:0.002688:0.002688:0.004556:0.007203:0.003723:0.002688:0.008198:0.003723:0.008158:0.006451:0.003723:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723
(8.2% :@0.394212:0.909744:0.431923:0.909744:0.431923:0.895715:0.394212:0.895715:0.004959:0.007445:0.003723:0.007445:0.010415:0.003723
vs.:@0.431923:0.909744:0.448305:0.909744:0.448305:0.895715:0.431923:0.895715:0.007445:0.005214:0.003723
 9.6% in placebo  group:@0.448305:0.909744:0.611805:0.909744:0.611805:0.895715:0.448305:0.895715:0.003723:0.007445:0.003723:0.007445:0.010415:0.003723:0.002688:0.008198:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723:0.013036:0.009045:0.004045:0.008803:0.008171:0.009165
group; HR 0.85; 95% Cl :@0.394212:0.922572:0.541814:0.922572:0.541814:0.908543:0.394212:0.908543:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723:0.003723:0.009179:0.008158:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.003723:0.007445:0.007445:0.010415:0.003723:0.010926:0.002688:0.003723
0.74-0.97; p = 0.02:@0.394212:0.935400:0.507840:0.935400:0.507840:0.921371:0.394212:0.921371:0.007445:0.003723:0.007445:0.007445:0.004462:0.007445:0.003723:0.007445:0.007445:0.003723:0.003723:0.007956:0.003723:0.008144:0.003723:0.007445:0.003723:0.007445:0.007445
Increased risk of retino-:@0.572577:0.884087:0.721993:0.884087:0.721993:0.870058:0.572577:0.870058:0.003037:0.008198:0.008695:0.004045:0.008735:0.009179:0.005214:0.008735:0.009206:0.003723:0.004045:0.002688:0.005214:0.006746:0.003723:0.008803:0.004220:0.003723:0.004045:0.008735:0.004556:0.002688:0.008198:0.008803:0.004462
pathy in semaglutide :@0.572577:0.896915:0.713755:0.896915:0.713755:0.882886:0.572577:0.882886:0.009165:0.009179:0.004556:0.008198:0.007203:0.003723:0.002688:0.008198:0.003723:0.005214:0.008735:0.012606:0.009179:0.009045:0.002688:0.008171:0.004556:0.002688:0.009206:0.008735:0.003723
figure 8. liraglutide primary outcomes and death from :@0.076190:0.236042:0.477450:0.236042:0.477450:0.219543:0.076190:0.219543:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.004233:0.004233:0.006652:0.003629:0.004838:0.009979:0.009979:0.003629:0.009071:0.004536:0.003629:0.009979:0.009676:0.004233:0.009979:0.004838:0.003629:0.014212:0.009979:0.004838:0.008769:0.004233:0.009676:0.009071:0.004536:0.009676:0.009676:0.014212:0.009676:0.006652:0.004233:0.009979:0.009071:0.009979:0.004233:0.009979:0.009676:0.009979:0.004536:0.009071:0.004233:0.004233:0.004838:0.009676:0.014212:0.004233
cardiovascular causes:@0.076190:0.251778:0.242197:0.251778:0.242197:0.235280:0.076190:0.235280:0.009676:0.009979:0.004838:0.009979:0.003629:0.009676:0.008467:0.009979:0.006652:0.009676:0.009071:0.003629:0.009979:0.004838:0.004233:0.009676:0.009979:0.009071:0.006652:0.009676:0.006652
sustAin 6 (semaglutide and Cardiovascular Outcomes :@0.090478:0.282385:0.485160:0.282385:0.485160:0.265887:0.090478:0.265887:0.007711:0.009525:0.007711:0.006199:0.011037:0.004082:0.011037:0.002978:0.008315:0.002978:0.005594:0.007711:0.009525:0.014061:0.009827:0.009827:0.003477:0.008920:0.004385:0.003477:0.009827:0.009525:0.002978:0.009827:0.008920:0.009827:0.002978:0.011642:0.009827:0.004687:0.009827:0.003477:0.009525:0.008315:0.009827:0.006501:0.009525:0.008920:0.003477:0.009827:0.004687:0.002978:0.012549:0.008920:0.004385:0.009525:0.009525:0.014061:0.009525:0.006652:0.004233
in Patients with type 2 Diabetes).:@0.076190:0.297602:0.317641:0.297602:0.317641:0.281104:0.076190:0.281104:0.003477:0.008920:0.005836:0.008315:0.009827:0.004385:0.003477:0.009525:0.008920:0.004385:0.006501:0.005836:0.011944:0.003477:0.004385:0.008920:0.005836:0.006199:0.008618:0.009827:0.009525:0.005836:0.008315:0.005836:0.010432:0.003477:0.009827:0.009827:0.009525:0.004385:0.009525:0.006501:0.005594:0.004233
17:@0.317451:0.292305:0.327185:0.292305:0.327185:0.282736:0.317451:0.282736:0.004823:0.004911
 The results for sema-:@0.327098:0.297603:0.480934:0.297603:0.480934:0.281821:0.327098:0.281821:0.005760:0.006290:0.009071:0.009676:0.005760:0.004400:0.009676:0.005715:0.009041:0.002873:0.004974:0.005715:0.005760:0.004596:0.009752:0.004400:0.005760:0.005715:0.009676:0.014030:0.010175:0.005020
glutide for the primary MACE outcomes (26% reduction) :@0.076197:0.312820:0.485213:0.312820:0.485213:0.297038:0.076197:0.297038:0.010024:0.002873:0.009041:0.004974:0.002873:0.010205:0.009676:0.004853:0.004596:0.009752:0.004400:0.004853:0.004974:0.009071:0.009676:0.004853:0.008799:0.004400:0.002873:0.014030:0.010175:0.004400:0.007953:0.004853:0.013743:0.011037:0.012141:0.007953:0.004853:0.009752:0.009041:0.004974:0.009631:0.009752:0.014030:0.009676:0.005715:0.004853:0.005428:0.008225:0.008225:0.011566:0.004853:0.004400:0.009676:0.010205:0.009041:0.009631:0.004974:0.002873:0.009752:0.009071:0.005579:0.004188
are statistically significant (see Figure 9). Weight loss was :@0.076197:0.328037:0.485122:0.328037:0.485122:0.312255:0.076197:0.312255:0.010175:0.004400:0.009676:0.004778:0.005715:0.004974:0.010175:0.004974:0.002873:0.005715:0.004974:0.002873:0.009631:0.010175:0.002873:0.002873:0.007953:0.004778:0.005715:0.002873:0.010024:0.009071:0.002873:0.003606:0.003606:0.009631:0.010175:0.009071:0.004974:0.004778:0.005428:0.005715:0.009676:0.009676:0.004778:0.007182:0.002873:0.010024:0.009041:0.004400:0.009676:0.004778:0.008225:0.005428:0.004037:0.004778:0.014363:0.009676:0.002873:0.010024:0.009071:0.004974:0.004778:0.002873:0.009752:0.005715:0.005715:0.004778:0.012413:0.010175:0.005866:0.004188
also greater in this trial, as compared to the LEADER trial. :@0.076197:0.343254:0.485122:0.343254:0.485122:0.327471:0.076197:0.327471:0.010175:0.002873:0.005715:0.009752:0.004324:0.010024:0.004400:0.009676:0.010175:0.004974:0.009676:0.004400:0.004324:0.002873:0.009071:0.004324:0.004974:0.009071:0.002873:0.005715:0.004324:0.004974:0.004400:0.002873:0.010175:0.002873:0.004037:0.004324:0.010175:0.005715:0.004324:0.009631:0.009752:0.014030:0.010160:0.010175:0.004400:0.009676:0.010205:0.004324:0.004974:0.009752:0.004324:0.004974:0.009071:0.009676:0.004324:0.006834:0.007953:0.011037:0.011097:0.007953:0.009026:0.004324:0.004974:0.004400:0.002873:0.010175:0.002873:0.004188:0.004188
Further trials in the future are being planned for this drug.:@0.076197:0.358471:0.480239:0.358471:0.480239:0.342688:0.076197:0.342688:0.007182:0.009041:0.004400:0.004974:0.009071:0.009676:0.004400:0.004037:0.004974:0.004400:0.002873:0.010175:0.002873:0.005715:0.004037:0.002873:0.009071:0.004037:0.004974:0.009071:0.009676:0.004037:0.004596:0.009041:0.004974:0.009041:0.004400:0.009676:0.004037:0.010175:0.004400:0.009676:0.004037:0.010160:0.009676:0.002873:0.009071:0.010024:0.004037:0.010160:0.002873:0.010175:0.009071:0.009071:0.009676:0.010205:0.004037:0.004596:0.009752:0.004400:0.004037:0.004974:0.009071:0.002873:0.005715:0.004037:0.010205:0.004400:0.009041:0.010024:0.004188
exsCel: effects of once-weekly exenatide on cardio-:@0.533333:0.084931:0.923812:0.084931:0.923812:0.068433:0.533333:0.068433:0.007862:0.010281:0.007862:0.011793:0.007862:0.006652:0.004233:0.004747:0.007862:0.004233:0.004233:0.009676:0.009676:0.004536:0.006652:0.004747:0.009676:0.004233:0.004747:0.009676:0.009071:0.009676:0.009676:0.006350:0.012095:0.009676:0.009676:0.008769:0.003629:0.008769:0.004762:0.009676:0.008467:0.009676:0.009071:0.009979:0.004536:0.003629:0.009979:0.009676:0.004762:0.009676:0.009071:0.004762:0.009676:0.009979:0.004838:0.009979:0.003629:0.009676:0.006350
vascular  outcomes  in  type  2  diabetes.:@0.519045:0.100090:0.820065:0.100090:0.820065:0.083592:0.519045:0.083592:0.008467:0.009979:0.006652:0.009676:0.009071:0.003629:0.009979:0.004838:0.004233:0.004385:0.009676:0.009071:0.004536:0.009676:0.009676:0.014212:0.009676:0.006652:0.004233:0.004385:0.003629:0.009071:0.004233:0.004385:0.004536:0.008769:0.009979:0.009676:0.004233:0.004385:0.008467:0.004233:0.004385:0.009979:0.003629:0.009979:0.009979:0.009676:0.004536:0.009676:0.006652:0.004233
18:@0.820095:0.094790:0.829917:0.094790:0.829917:0.085221:0.820095:0.085221:0.004911:0.004911
 For primary :@0.829918:0.100089:0.927995:0.100089:0.927995:0.084306:0.829918:0.084306:0.008527:0.007333:0.009903:0.004551:0.008527:0.010311:0.004551:0.003024:0.014182:0.010326:0.004551:0.008104:0.004188
cardiovascular outcomes,  all-cause mortality,  death :@0.519040:0.115248:0.927995:0.115248:0.927995:0.099465:0.519040:0.099465:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.009661:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.004188:0.004188:0.005458:0.010326:0.003024:0.003024:0.005020:0.009782:0.010326:0.009192:0.005866:0.009827:0.009661:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.004188:0.005458:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188
from cardiovascular causes and hospitalisation for heart :@0.519040:0.130407:0.927965:0.130407:0.927965:0.114625:0.519040:0.114625:0.004747:0.004551:0.009903:0.014182:0.003266:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.003281:0.009782:0.010326:0.009192:0.005866:0.009827:0.005866:0.003281:0.010326:0.009223:0.010357:0.003281:0.009223:0.009903:0.005866:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005866:0.010326:0.005125:0.003024:0.009903:0.009223:0.003281:0.004747:0.009903:0.004551:0.003266:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188
failure (see Figure 10).:@0.519040:0.145566:0.678017:0.145566:0.678017:0.129784:0.519040:0.129784:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.005579:0.005866:0.009827:0.009827:0.004188:0.007333:0.003024:0.010175:0.009192:0.004551:0.009827:0.004188:0.008376:0.008376:0.005579:0.004188
Key tHerAPy COnsiDerAtiOns::@0.519047:0.187164:0.800295:0.187164:0.800295:0.166999:0.519047:0.166999:0.011457:0.009609:0.011457:0.005174:0.007761:0.012566:0.009609:0.010718:0.013674:0.010348:0.011457:0.005174:0.014413:0.015522:0.013674:0.009609:0.005174:0.012935:0.009609:0.010718:0.013674:0.007761:0.005174:0.015522:0.013674:0.009609:0.005174
A summAry :@0.519047:0.207455:0.633616:0.207455:0.633616:0.187291:0.519047:0.187291:0.013674:0.005174:0.009609:0.011826:0.016631:0.016631:0.013674:0.010718:0.011457:0.005174
The current standard of therapy for type 2 diabetes :@0.519047:0.224388:0.927972:0.224388:0.927972:0.208606:0.519047:0.208606:0.006743:0.009525:0.010130:0.006305:0.010084:0.009495:0.004853:0.004853:0.010130:0.009525:0.005428:0.006305:0.006169:0.005428:0.010629:0.009525:0.010659:0.010629:0.004853:0.010659:0.006305:0.010205:0.005050:0.006305:0.005428:0.009525:0.010130:0.004853:0.010629:0.010614:0.008406:0.006305:0.005050:0.010205:0.004853:0.006305:0.005428:0.008406:0.010614:0.010130:0.006305:0.008678:0.006305:0.010659:0.003326:0.010629:0.010614:0.010130:0.005428:0.010130:0.005866:0.004188
recommends initiation of therapy with metformin at :@0.519047:0.239547:0.928047:0.239547:0.928047:0.223765:0.519047:0.223765:0.004853:0.010130:0.010084:0.010205:0.014484:0.014484:0.010130:0.009525:0.010659:0.006169:0.006804:0.003326:0.009525:0.003326:0.005428:0.003326:0.010629:0.005428:0.003326:0.010205:0.009525:0.006804:0.010205:0.005050:0.006804:0.005428:0.009525:0.010130:0.004853:0.010629:0.010614:0.008406:0.006804:0.012866:0.003326:0.005428:0.009525:0.006804:0.014484:0.010130:0.005428:0.005050:0.010205:0.004853:0.014484:0.003326:0.009525:0.006804:0.010629:0.005125:0.004188
the time of diagnosis. :@0.519047:0.254707:0.685085:0.254707:0.685085:0.238924:0.519047:0.238924:0.005428:0.009525:0.010130:0.004490:0.005428:0.003326:0.014484:0.010130:0.004490:0.010205:0.005050:0.004490:0.010659:0.003326:0.010629:0.010477:0.009525:0.010205:0.006169:0.003326:0.006169:0.004188:0.004188
•  If glycaemic targets are not reached (HbA1 <:@0.519047:0.269866:0.892740:0.269861:0.892740:0.254078:0.519047:0.254083:0.009465:0.004188:0.006501:0.003719:0.005050:0.004521:0.010477:0.003326:0.008406:0.010084:0.010629:0.010130:0.014484:0.003326:0.010084:0.004521:0.005428:0.010629:0.004853:0.010477:0.010130:0.005428:0.006169:0.004521:0.010629:0.004853:0.010130:0.004521:0.009525:0.010205:0.005428:0.004521:0.004853:0.010130:0.010629:0.010084:0.009525:0.010130:0.010659:0.004521:0.005881:0.010629:0.010614:0.011490:0.008376:0.010654:0.093224
c:@0.873208:0.269527:0.878882:0.269527:0.878882:0.260373:0.873208:0.260373:0.005674
  7%), :@0.879057:0.269861:0.927997:0.269861:0.927997:0.254078:0.879057:0.254078:0.004188:0.009797:0.008678:0.012020:0.005881:0.004188:0.004188
a second drug is commenced. It is usually a sulph-:@0.539211:0.285020:0.923809:0.285020:0.923809:0.269238:0.539211:0.269238:0.010629:0.004853:0.006169:0.010130:0.010084:0.010205:0.009525:0.010659:0.004853:0.010659:0.004853:0.009495:0.010477:0.004853:0.003326:0.006169:0.004853:0.010084:0.010205:0.014484:0.014484:0.010130:0.009525:0.010084:0.010130:0.010659:0.004490:0.004853:0.003719:0.005428:0.004853:0.003326:0.006169:0.004853:0.009495:0.006169:0.009495:0.010629:0.003326:0.003326:0.008406:0.004853:0.010629:0.004853:0.006169:0.009495:0.003326:0.010614:0.009525:0.005020
onylurea  (a  modified-release  gliclazide  is  recom-:@0.539211:0.300179:0.923809:0.300179:0.923809:0.284397:0.539211:0.284397:0.010205:0.009525:0.008406:0.003326:0.009495:0.004853:0.010130:0.010629:0.004188:0.003296:0.005881:0.010629:0.004188:0.003296:0.014484:0.010205:0.010659:0.003326:0.003833:0.003833:0.010130:0.010659:0.005322:0.004853:0.010130:0.003326:0.010130:0.010629:0.006169:0.010130:0.004188:0.003296:0.010477:0.003326:0.003326:0.010084:0.003326:0.010629:0.006728:0.003326:0.010659:0.010130:0.004188:0.003296:0.003326:0.006169:0.004188:0.003296:0.004853:0.010130:0.010084:0.010205:0.014484:0.005020
mended).:@0.539211:0.315339:0.614867:0.315339:0.614867:0.299556:0.539211:0.299556:0.014484:0.010130:0.009525:0.010659:0.010130:0.010659:0.005881:0.004188
•  If hypoglycaemia is a problem, or treatment of the :@0.519058:0.330498:0.928058:0.330498:0.928058:0.314715:0.519058:0.314715:0.009465:0.004188:0.006501:0.003719:0.005050:0.004460:0.009525:0.008406:0.010614:0.010205:0.010477:0.003326:0.008406:0.010084:0.010629:0.010130:0.014484:0.003326:0.010629:0.004460:0.003326:0.006169:0.004460:0.010629:0.004460:0.010614:0.004853:0.010205:0.010614:0.003326:0.010130:0.014484:0.004490:0.004460:0.010205:0.004853:0.004460:0.005428:0.004853:0.010130:0.010629:0.005428:0.014484:0.010130:0.009525:0.005428:0.004460:0.010205:0.005050:0.004460:0.005428:0.009525:0.009827:0.004188
elderly is considered, a Dpp-4 Inhibitor is a good :@0.539211:0.345657:0.927982:0.345657:0.927982:0.329874:0.539211:0.329874:0.010130:0.003326:0.010659:0.010130:0.004853:0.003326:0.008406:0.007182:0.003326:0.006169:0.007182:0.010084:0.010205:0.009525:0.006169:0.003326:0.010659:0.010130:0.004853:0.010130:0.010659:0.004490:0.007182:0.010629:0.007182:0.011551:0.009253:0.009253:0.005322:0.008678:0.007182:0.003719:0.009525:0.009525:0.003326:0.010614:0.003326:0.005428:0.010205:0.004853:0.007182:0.003326:0.006169:0.007182:0.010629:0.007182:0.010477:0.010205:0.010205:0.010357:0.004188
choice, because of low hypoglycaemia risks. :@0.539211:0.360816:0.885437:0.360816:0.885437:0.345033:0.539211:0.345033:0.010084:0.009525:0.010205:0.003326:0.010084:0.010130:0.004490:0.004490:0.010614:0.010130:0.010084:0.010629:0.009495:0.006169:0.010130:0.004490:0.010205:0.005050:0.004490:0.003326:0.010205:0.012866:0.004490:0.009525:0.008406:0.010614:0.010205:0.010477:0.003326:0.008406:0.010084:0.010629:0.010130:0.014484:0.003326:0.010629:0.004490:0.004853:0.003326:0.006169:0.007892:0.006169:0.004188:0.004188
•  If weight is a problem, or the patient has established :@0.519058:0.375975:0.927997:0.375975:0.927997:0.360193:0.519058:0.360193:0.009465:0.004188:0.006501:0.003719:0.005050:0.003099:0.012866:0.010130:0.003326:0.010477:0.009525:0.005428:0.003099:0.003326:0.006169:0.003099:0.010629:0.003099:0.010614:0.004853:0.010205:0.010614:0.003326:0.010130:0.014484:0.004490:0.003099:0.010205:0.004853:0.003099:0.005428:0.009525:0.010130:0.003099:0.010614:0.010629:0.005428:0.003326:0.010130:0.009525:0.005428:0.003099:0.009525:0.010629:0.006169:0.003099:0.010130:0.006169:0.005428:0.010629:0.010614:0.003326:0.003326:0.006169:0.009525:0.010130:0.010357:0.004188
cardiovascular disease, consideration should be :@0.539211:0.391134:0.927982:0.391134:0.927982:0.375352:0.539211:0.375352:0.010084:0.010629:0.004853:0.010659:0.003326:0.010205:0.008678:0.010629:0.006169:0.010084:0.009495:0.003326:0.010629:0.004853:0.008845:0.010659:0.003326:0.006169:0.010130:0.010629:0.006169:0.010130:0.004490:0.008845:0.010084:0.010205:0.009525:0.006169:0.003326:0.010659:0.010130:0.004853:0.010629:0.005428:0.003326:0.010205:0.009525:0.008845:0.006169:0.009525:0.010205:0.009495:0.003326:0.010659:0.008845:0.010614:0.009827:0.004188
given to sGLT2 Inhibitors (tablets) or GLp-1 RA (sub-:@0.539211:0.406294:0.923855:0.406294:0.923855:0.390511:0.539211:0.390511:0.010477:0.003326:0.008678:0.010130:0.009525:0.004430:0.005428:0.010205:0.004430:0.007832:0.013486:0.007287:0.006743:0.008678:0.004430:0.003719:0.009525:0.009525:0.003326:0.010614:0.003326:0.005428:0.010205:0.004853:0.006169:0.004430:0.005881:0.005428:0.010629:0.010614:0.003326:0.010130:0.005428:0.006169:0.005881:0.004430:0.010205:0.004853:0.004430:0.013486:0.007287:0.009253:0.005322:0.008678:0.004430:0.009480:0.011490:0.004430:0.005881:0.006169:0.009495:0.010614:0.005020
cutaneous injection). sGLT2 inhibitors should not be :@0.539211:0.421453:0.928013:0.421453:0.928013:0.405670:0.539211:0.405670:0.010084:0.009495:0.005428:0.010629:0.009525:0.010130:0.010205:0.009495:0.006169:0.003810:0.003326:0.009525:0.003372:0.010130:0.010084:0.005428:0.003326:0.010205:0.009525:0.005881:0.004490:0.003810:0.007832:0.013486:0.007287:0.006743:0.008678:0.003810:0.003326:0.009525:0.009525:0.003326:0.010614:0.003326:0.005428:0.010205:0.004853:0.006169:0.003810:0.006169:0.009525:0.010205:0.009495:0.003326:0.010659:0.003810:0.009525:0.010205:0.005428:0.003810:0.010614:0.009827:0.004188
initiated if the eGFR is <60 ml/min/1.73 m:@0.539211:0.436612:0.846597:0.436612:0.846597:0.420829:0.539211:0.420829:0.003326:0.009525:0.003326:0.005428:0.003326:0.010629:0.005428:0.010130:0.010659:0.004490:0.003326:0.005050:0.004490:0.005428:0.009525:0.010130:0.004490:0.010130:0.013486:0.007635:0.009480:0.004490:0.003326:0.006169:0.004490:0.009465:0.008678:0.008678:0.004490:0.014484:0.003326:0.006909:0.014484:0.003326:0.009525:0.006909:0.008678:0.004490:0.008678:0.008678:0.004490:0.014182
2. :@0.846897:0.431296:0.856788:0.431296:0.856788:0.422142:0.846897:0.422142:0.005033:0.002429:0.002429
•  Cost considerations are also important in the selec:@0.519047:0.451753:0.918507:0.451753:0.918507:0.435970:0.519047:0.435970:0.009465:0.004188:0.006501:0.012594:0.010205:0.006169:0.005428:0.003825:0.010084:0.010205:0.009525:0.006169:0.003326:0.010659:0.010130:0.004853:0.010629:0.005428:0.003326:0.010205:0.009525:0.006169:0.003825:0.010629:0.004853:0.010130:0.003825:0.010629:0.003326:0.006169:0.010205:0.003825:0.003326:0.014484:0.010614:0.010205:0.004853:0.005428:0.010629:0.009525:0.005428:0.003825:0.003326:0.009525:0.003825:0.005428:0.009525:0.010130:0.003825:0.006169:0.010130:0.003326:0.010130:0.009782
-:@0.918810:0.451753:0.923829:0.451753:0.923829:0.435970:0.918810:0.435970:0.005020
tion of drugs. :@0.539201:0.466912:0.641950:0.466912:0.641950:0.451129:0.539201:0.451129:0.005428:0.003326:0.010205:0.009525:0.004490:0.010205:0.005050:0.004490:0.010659:0.004853:0.009495:0.010477:0.006169:0.004188:0.004188
•  In type 2 diabetes patients with established athero:@0.519047:0.482071:0.918447:0.482071:0.918447:0.466288:0.519047:0.466288:0.009465:0.004188:0.006501:0.003719:0.009525:0.003825:0.005428:0.008406:0.010614:0.010130:0.003810:0.008678:0.003825:0.010659:0.003326:0.010629:0.010614:0.010130:0.005428:0.010130:0.006169:0.003810:0.010614:0.010629:0.005428:0.003326:0.010130:0.009525:0.005428:0.006169:0.003810:0.012866:0.003326:0.005428:0.009525:0.003810:0.010130:0.006169:0.005428:0.010629:0.010614:0.003326:0.003326:0.006169:0.009525:0.010130:0.010659:0.003810:0.010629:0.005428:0.009525:0.010130:0.004853:0.009903
-:@0.918749:0.482071:0.923769:0.482071:0.923769:0.466288:0.918749:0.466288:0.005020
sclerotic  cardiovascular  disease,  the  ADA/EAsD :@0.539201:0.497230:0.927972:0.497230:0.927972:0.481447:0.539201:0.481447:0.006169:0.010084:0.003326:0.010130:0.004853:0.010205:0.005428:0.003326:0.010084:0.004188:0.005851:0.010084:0.010629:0.004853:0.010659:0.003326:0.010205:0.008678:0.010629:0.006169:0.010084:0.009495:0.003326:0.010629:0.004853:0.004188:0.005851:0.010659:0.003326:0.006169:0.010130:0.010629:0.006169:0.010130:0.004490:0.004188:0.005851:0.005428:0.009525:0.010130:0.004188:0.005851:0.011490:0.011551:0.011490:0.006909:0.008406:0.011490:0.007832:0.011249:0.004188
Guidelines recommend the choice of empagliflo:@0.539201:0.512389:0.918462:0.512389:0.918462:0.496607:0.539201:0.496607:0.013486:0.009495:0.003326:0.010659:0.010130:0.003326:0.003326:0.009525:0.010130:0.006169:0.006184:0.004853:0.010130:0.010084:0.010205:0.014484:0.014484:0.010130:0.009525:0.010659:0.006184:0.005428:0.009525:0.010130:0.006184:0.010084:0.009525:0.010205:0.003326:0.010084:0.010130:0.006184:0.010205:0.005050:0.006184:0.010130:0.014484:0.010614:0.010629:0.010477:0.003326:0.003326:0.003818:0.003818:0.009903
-:@0.918764:0.512389:0.923784:0.512389:0.923784:0.496607:0.918764:0.496607:0.005020
zin  as  the  sGLT2  inhibitor  of  choice,  or  liraglutide :@0.539201:0.527548:0.927972:0.527548:0.927972:0.511766:0.539201:0.511766:0.006728:0.003326:0.009525:0.004188:0.002827:0.010629:0.006169:0.004188:0.002827:0.005428:0.009525:0.010130:0.004188:0.002842:0.007832:0.013486:0.007287:0.006743:0.008678:0.004188:0.002827:0.003326:0.009525:0.009525:0.003326:0.010614:0.003326:0.005428:0.010205:0.004853:0.004188:0.002827:0.010205:0.005050:0.004188:0.002827:0.010084:0.009525:0.010205:0.003326:0.010084:0.010130:0.004490:0.004188:0.002827:0.010205:0.004853:0.004188:0.002827:0.003326:0.003326:0.004853:0.010629:0.010477:0.003326:0.009495:0.005428:0.003326:0.010659:0.009827:0.004188
as the GLp-1 RA of choice because of their docu-:@0.539201:0.542708:0.923814:0.542708:0.923814:0.526925:0.539201:0.526925:0.010629:0.006169:0.005322:0.005428:0.009525:0.010130:0.005322:0.013486:0.007287:0.009253:0.005322:0.008678:0.005322:0.009480:0.011490:0.005322:0.010205:0.005050:0.005322:0.010084:0.009525:0.010205:0.003326:0.010084:0.010130:0.005322:0.010614:0.010130:0.010084:0.010629:0.009495:0.006169:0.010130:0.005322:0.010205:0.005050:0.005322:0.005428:0.009525:0.010130:0.003326:0.004853:0.005322:0.010659:0.010205:0.010084:0.009495:0.005020
mented, beneficial :@0.539201:0.558375:0.688154:0.558375:0.688154:0.542592:0.539201:0.542592:0.014484:0.010130:0.009525:0.005428:0.010130:0.010659:0.004490:0.004490:0.010614:0.010130:0.009525:0.010130:0.003833:0.003833:0.010084:0.003326:0.010629:0.003326:0.004188
cardiovascular effects.:@0.688456:0.558375:0.862794:0.558375:0.862794:0.542592:0.688456:0.542592:0.010084:0.010629:0.004853:0.010659:0.003326:0.010205:0.008678:0.010629:0.006169:0.010084:0.009495:0.003326:0.010629:0.004853:0.004490:0.010130:0.005050:0.005050:0.010130:0.010084:0.005428:0.006169:0.004188
19:@0.863087:0.553070:0.872978:0.553070:0.872978:0.543916:0.863087:0.543916:0.005033:0.004858
figure 9. semaglutide primary outcome:@0.080381:0.558143:0.369457:0.558143:0.369457:0.541645:0.080381:0.541645:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.004233:0.004233:0.007862:0.009676:0.014212:0.009979:0.009979:0.003629:0.009071:0.004536:0.003629:0.009979:0.009676:0.004233:0.009979:0.004838:0.003629:0.014212:0.009979:0.004838:0.008769:0.004233:0.009676:0.009071:0.004536:0.009676:0.009676:0.014212:0.009676
World of Example. ponywatches.com:@0.076190:0.945871:0.222349:0.945871:0.222349:0.937103:0.076190:0.937103:0.007879:0.005317:0.002343:0.001495:0.005569:0.002142:0.005317:0.002453:0.002142:0.004317:0.003847:0.005552:0.007694:0.005544:0.001495:0.005275:0.002142:0.002142:0.004788:0.005317:0.004939:0.004317:0.006795:0.005552:0.002663:0.005250:0.004939:0.005275:0.003074:0.002142:0.005250:0.005317:0.007879